PRODUCT INFORMATION

 
BRCA Testing

A test that analyzes BRCA 1 and BRCA 2 genes associated with potential risks for breast, ovaries, pancreas and prostate cancers.


Our BRCA testing kit consists of sequencing the full BRCA 1/2 genes using Next Generation Sequencing and analyzing all gene sequences using Bioinformatics tool to detect the genetic mutations.


Moreover, our target enrichment method allows to specifically isolate the BRCA 1,2 genomic loci out of the whole exome and thereby increases the sensitivity of detecting genetic mutations by producing higher coverage & depth sequencing data.

Around half of hereditary breast and ovarian cancers caused by the mutations in the BRCA1,2 genes.
 

The BRCA 1,2 genes function as a tumor suppressor, thereby they have an essential role in both DNA repair and cell cycle control systems.

 

And the studies have shown the BRCA1,2 gene mutation carriers have potential risk to develop specific cancers.

  

  • 40%-80% for breast cancer

  • 11%-40% for ovarian cancer

  • 1%-10% for male breast cancer

  • Up to 39% for prostate cancer

  • 1%-7% for pancreatic cancer   

 

 

 

 

 

 

Test Results

- Analysis of Single Nucleotide Variation, Insertion/deletion

 
Cancer Screening Kit

A comprehensive test that analyzes about 40 genes that are associated over Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, Prostate and Lung cancers.


Our Cancer Screening consists of sequencing the full 40 oncogenes using Next Generation Sequencing and analyzing all gene sequences Bioinformatics tool to detect the genetic mutations.


Moreover, our target enrichment method allows to specifically isolate the 40 oncogenes genomic loci out of the whole exome and thereby increases the sensitivity of detecting genetic mutations by producing higher coverage & depth sequencing data.

 

Studies have shown the specific gene mutation carriers have potential risk to develop certain types of cancers.

For instance,

  • CDHI mutations are known to be associated with hereditary diffuse gastric cancer. And mutation carriers have a 67% for men and 83% for women lifetime risk of developing cancer by age 80.

  • TP53 mutations are known to be associated with Li-Fraumeni syndrome. And the TP53 mutation carriers have a 21-49% lifetime risk of developing cancer by age 30 and a lifetime cancer risk of 68-93%.

 

Our Hereditary Cancer testing panel is designed to analyze 31 genes related to breast, ovarian, colorectal, endometrial, melanoma, pancreatic, gastric, prostate and lung cancers. Our panel specifically isolates CDS regions of 31 oncogenes, thereby increasing the detection sensitivity of genetic mutations.

 
Customization Kit

Celemics' have come up with the most convenient kit for hospitals or labs with special needs.  If you can't find kits in hand, if you provide us with the gene lists, we can help design a kit separately for users.

Celemics' will also make sure the kits are rebalanced for best results so you will not receive data that is unreadable.  

Customized Panel

•Unparalleled flexibility in designing your own test by specifically isolating your genomic loci of interest.

 

TopQXSEP MagBead is an ideal matrix that can be used in various types of DNA purification.Nucleic acid, which is refined using TopQXSEP MagBead, can be applied in various experiments (e.g. manipulation, PCR, and DNA sequencing).

TopQXSEP MagBead binds DNA selectively, which protects DNA from potential inhibitors or contaminants by short incubation processes (i.e. selective integration with DNA). After purification washes, DNA receives selective protection and remains with beads.

TOPQXSEP

Please leave us your comment or questions.  We will reply you as soon as possible.  Please don't forget your contact as well.

MediTrust, All rights reserved.

 

  • Wix Facebook page